Front. Cell Dev. Biol. Frontiers in Cell and Developmental Biology Front. Cell Dev. Biol. 2296-634X Frontiers Media S.A. 10.3389/fcell.2020.00565 Cell and Developmental Biology Review Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia Zhou Daipeng 1 Wang Lei 1 Cui Qingbin 2 Iftikhar Ryma 2 Xia Yanfei 3 * Xu Peng 3 * 1Department of Anesthesiology, Pinghu First People’s Hospital, Jiaxing, China 2College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United States 3Department of Anesthesiology, Zhejiang Hospital, Hangzhou, China

Edited by: Carlos Pérez-Plasencia, National Autonomous University of Mexico, Mexico

Reviewed by: Kenneth K. W. To, The Chinese University of Hong Kong, China; Alan Talevi, National University of La Plata, Argentina

 *Correspondence: Yanfei Xia, xiayf0303@126.com Peng Xu, xupengugra@163.com

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Cell and Developmental Biology

 17 07 2020 2020 8 565 04 04 2020 15 06 2020 Copyright © 2020 Zhou, Wang, Cui, Iftikhar, Xia and Xu. 2020 Zhou, Wang, Cui, Iftikhar, Xia and Xu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

While cancer treatment has improved dramatically, it has also encountered many critical challenges, such as disease recurrence, metastasis, and drug resistance, making new drugs with novel mechanisms an urgent clinical need. The term “drug repositioning,” also known as old drugs for new uses, has emerged as one practical strategy to develop new anticancer drugs. Anesthetics have been widely used in surgical procedures to reduce the excruciating pain. Lidocaine, one of the most-used local anesthetics in clinical settings, has been found to show multi-activities, including potential in cancer treatment. Growing evidence shows that lidocaine may not only work as a chemosensitizer that sensitizes other conventional chemotherapeutics to certain resistant cancer cells, but also could suppress cancer cells growth by single use at different doses or concentrations. Lidocaine could suppress cancer cell growth in vitro and in vivo via multiple mechanisms, such as regulating epigenetic changes and promoting pro-apoptosis pathways, as well as regulating ABC transporters, metastasis, and angiogenesis, etc., providing valuable information for its further application in cancer treatment and for new drug discovery. In addition, lidocaine is now under clinical trials to treat certain types of cancer. In the current review, we summarize the research and analyze the underlying mechanisms, and address key issues in this area.

 drug repositioning lidocaine chemosensitizer anticancer mechanisms Introduction

Cancer treatments have made dramatic progress and achieved tremendous success for the last seven decades as a result of the development of conventional therapies, including surgery, chemotherapy, radiotherapy (DeVita and Chu, 2008), and innovative targeted small-molecule tyrosine kinase inhibitors (Prasad et al., 2016; Lee et al., 2018), as well as the cutting-edge immunotherapy (Macchiarulo, 2017; Harjes, 2018). The quality of life of cancer patients has improved significantly by precisely eliminating cancer cells without harming normal cells (Re et al., 2018; Salgado et al., 2018). However, many challenges remain to be solved (Figure 1). Examples include the low response rate, even in those patients with positive tyrosine kinases mutations or with programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) (Prasad et al., 2016; Sambi et al., 2019). Other challenges include cancer recurrence and target mutations, as well as the skyrocketing financial pressure, etc. Another major ominous issue in cancer chemotherapy is multi-drug resistance (MDR), which is harnessed by cancer cells to become resistant to various chemotherapeutics (Pavan et al., 2014; Riganti et al., 2015). Various strategies have been developed to address these challenges (Bode and Dong, 2018; Cui et al., 2018a, 2019b; Karlovich and Williams, 2019; Wise and Solit, 2019). Generations of selective chemotherapeutics and monoclonal antibodies have been developed to improve the response rate, and diminish adverse effects (DeVita and Chu, 2008; Palazzo et al., 2010; Mittra and Moscow, 2019). MDR can be induced by many factors, such as the activated defensive system which eliminates reactive oxygen species (ROS) caused by various chemotherapeutics (Cui et al., 2018a); the overexpression of ATP-binding cassette (ABC) transporters which transport their substrates, including many anticancer drugs via a mechanism known as efflux to reduce the concentrations of various chemotherapeutics (Li et al., 2016; Mottino, 2019); and the provoked DNA repair to become resistance to antimetabolite and certain tyrosine kinase inhibitors (TKIs) (Nikitaki et al., 2015; Sun et al., 2018), as well as up-regulated anti-apoptotic enzymes (Adams et al., 2018), etc. Each of these mechanisms could be countered (totally or partially) by specific strategies, such as drug combinations, although the drug–drug interactions and further drug resistance are still unavoidable. Novel anticancer agents remain unmet clinical needs.

Cancer treatment and critical challenges.

Other novel anticancer drugs discovery strategies include the old drugs repositioning (Pushpakom et al., 2018). Drug repositioning, also known as old drugs for new uses, is a strategy to identify the novel application of approved drugs that have been assessed for safety and efficacy (to their original indications) (Serafin et al., 2019), resulting in low-cost and low-risk new drug development. Successful examples in preclinical/clinical trials include the combination of conventional chemotherapeutics with certain TKIs (Fan et al., 2018; Cui et al., 2019a, Wang et al., 2020), phosphodiesterase-5 inhibitors (Tiwari and Chen, 2013), and natural products, such as supplemental flavonoids (Cui et al., 2018b; Ye Q. et al., 2019), at various concentrations, to overcome certain MDR mediated by ABC transporters. Recently, local anesthetics and their applications in cancer treatment have attracted much interest (Nowacka and Borczyk, 2019; Yap et al., 2019). These compounds are found to work either as chemo-sensitizers, or by single use as cancer cell growth suppressor. In this review, we would like to summarize and discuss those studies of lidocaine, one of the most commonly used local anesthetics in clinical settings, and focus on its applications and mechanisms in cancer treatment.

 Lidocaine in Cancer Treatment

Originally, anesthetics are used to suppress the excruciating pain during various surgeries. Meanwhile, these anesthetics also possess other functions, examples include lidocaine. As it has been shown that through different mechanisms, such as sodium channel inhibitor and the regulation of G protein-coupled receptors, lidocaine exerts its multifunctional effects in anti-inflammation (Caracas et al., 2009; Cruz et al., 2017), analgesia and antihyperalgesia (Tian et al., 2009), immuno-modulation (Kim et al., 2017), anti-arrhythmia (Harrison and Collinsworth, 1974), and as an antibacterial (Begec et al., 2007). Importantly, as the focus of current review, growing evidence suggests that local anesthetics may also provide benefits in the treatment of cancer by inhibiting proliferation, invasion, and migration of certain cancer cells (Grandhi and Perona, 2019). Literatures show that lidocaine is not only able to kill various types of cancer cells, but has also been reported to sensitize various chemotherapeutics to many types of resistant cancer cells.

Lidocaine Sensitizes Cisplatin in Inducing Apoptosis via Multiple Pathways

A recent study demonstrated the sensitizing effects of lidocaine to cisplatin on human breast cancer lines MCF-7 and MDA-MB-231, a highly aggressive triple-negative breast cancer (TNBC) cell line that exhibits certain MDR properties (Koh et al., 2019; Thi-Kim et al., 2019). As shown in this research, lidocaine (0.01–1 mM), when combined with cisplatin, significantly enhanced the apoptosis ratio and the inhibitory effects of cisplatin on MCF-7 and MDA-MB-231 cells. The combination also suppressed the colony formation of MCF-7 and MDA-MB-231 cells. The results of combination therapy were much better than single administration of either lidocaine or cisplatin. The Western blot assay indicated, after co-treatment with lidocaine and cisplatin, higher expression of activated caspase-3 that regulated apoptosis, cleaved poly (ADP-ribose) polymerase (PARP) that promoted DNA repair, and cytochrome c (apoptosis modulator) was released from the mitochondria in MCF-7 cells were induced. Mechanistic studies revealed that lidocaine could suppress the methylation of certain genes, such as retinoic acid receptor β2 (RARβ2) and Ras association domain family 1 isoform A (RASSF1A), two promoters of tumor-suppressive genes. These findings in the present study indicated that, via suppression of RARβ2 and RASSF1A methylation, lidocaine sensitized cisplatin to breast cancer cells (Li et al., 2014).

Overexpression of miR-21 could regulate the phosphatase and tensin homolog (PTEN)/phosphoinositide-3-kinase (PI3K)/protein kinase B (PKB, or AKT) and programmed cell death 4 (PDCD4)/c-Jun N-terminal kinase (JNK) pathways, which are pivotal to cancer cells growth in cisplatin-resistant non-small cells lung cancer (NSCLC) A549/DDP cells (Ren et al., 2016). A study found that lidocaine alleviated cisplatin resistance and exhibited good inhibitory effects on the cell viability and cell migration and invasion at 10 μM. Mechanistic study indicated that the inhibitory effects were attributed to the induction of remarkable apoptosis by down-regulating mi-R-21 on A549/DDP cells—similar results as mi-R-21 inhibitor. The inhibition of mi-R-21 induced by lidocaine finally lead to the suppression of PTEN/PI3K/AKT and PDCD4/JNK pathways, leading to the resensitizing of cisplatin to A549/DDP cells (Yang Q. et al., 2019).

Multi-metastasis is one of the leading causes that result in mortality among breast cancer patients (Medeiros and Allan, 2019). Freeman et al. set out to determine the metastasis upon treatment of lidocaine/cisplatin by single or combinationary use in 4T1 cells xenograft mice model. Their results indicated that, compared to the control and cisplatin groups, the number of lung metastasis colony count was significantly reduced by the combination of cisplatin (3 mg/kg) and lidocaine (1.5 mg/kg); meanwhile, it didn’t impact the vascular endothelial growth factor (VEGF), a factor that is closely involved in cancer growth and migration (Eroglu et al., 2017), and the level of interleukin-6 (IL-6), an pro-inflammatory cytokine that promotes migration (He et al., 2018), as tested in serum. This study provided evidence that lidocaine might suppress metastasis in a breast cancer model, warranting further study for the underlying acting mechanisms and further evaluation in preclinical trials (Freeman et al., 2018).

Given its ability in sensitizing cisplatin in the cancer treatment, certain pharmaceutical formulations have been developed to achieve the co-delivery of lidocaine and cisplatin, including nanoparticles that possess well-controlled loading capacities and cancer-targeting properties (Swain et al., 2016; Wen et al., 2017). One nanogel system modified on cRGDfk, a peptide segment-cRGDfk with high affinity to αvβ3 integrin, was designed by Gao et al. and tested in chemo-resistant MDA-MB-231 breast cancer cells. This nanogel system (optimized concentration of 10 μM cisplatin and 50 μM lidocaine) demonstrated enhanced cytotoxic effects toward MDA-MB-231 cells by inducing substantial apoptosis in vitro. The combination therapy suppressed the metastasis of MDA-MB-231 breast cancer cells in xenograft mouse model with 6 mg/kg of cisplatin and 24 mg/kg of lidocaine via intravenous administration. In addition, this nanogel system showed a favorable safety profile, as it alleviated body-weight loss upon single use of cisplatin. More importantly, this nanogel system also succeeded in targeting accumulation in tumor tissues, as well as in the inhibition of tumor growth. The nanogel system provided a new therapy regimen for the treatment of breast cancer that overexpressed αvβ3 integrin (Gao et al., 2018).

 Lidocaine Sensitizes 5-Fluorouracil

Lidocaine also demonstrates sensitizing effects toward other chemotherapeutics, such as 5-fluorouracil (5-FU) (Wang et al., 2017) and mitomycin C (Yang X. et al., 2018).

In a study conducted by Wang et al. on the SK-MEL-2 melanoma cell line, although lidocaine (0–100 μM) exert limited toxic effects, its combination with 5-FU significantly enhanced the anticancer potency and apoptosis induction effects of 5-FU. Further mechanistic studies revealed that the overexpression of miR-493, and its target gene, Sox4, alone with the decreased levels of phosphined PI3K, AKT, and Smad2/3, conferred the re-sensitizing of SK-MEL-2 cells to 5-FU by lidocaine. This research indicated that lidocaine sensitized melanoma cells to 5-FU via the up-regulation of miR-493 and the down-regulation of Sox4-mediated PI3K/AKT and Smad pathways (Wang et al., 2017).

Recently, Zhang et al. reported that lidocaine might regulate ABC transporters proteins, leading to the sensitizing of 5-FU to choriocarcinoma cells (Zhang et al., 2019). As shown in this study, lidocaine (10–1,000 μM) exhibited limited toxic effects to human choriocarcinoma JEG-3 and JAR cells (with only moderate cytotoxic effects at 1,000 μM), while when combined (1, 10, and 100 μM) with 5-FU at non-toxic concentrations, it enhanced the sensitivity of 5-FU to these two cell lines via increased induction of apoptosis. Importantly, lidocaine down-regulated the levels of breast cancer resistance protein (BCRP or ABCG2), P-gp, multidrug resistance-associated protein 1 (MRP1), and MRP2 in cancer cells, probably via the inactivation of PI3K/AKT pathway, as confirmed by Western blot analysis. The overexpression of ABCG2 could antagonize the lidocaine induced sensitizing effects and inactivated PI3K/AKT pathway (Zhang et al., 2019), indicating 5-FU to be a substrate of ABCG2, and lidocaine might impact the efflux function of ABCG2 (Tang et al., 2017). This study provided interesting information for the reversal of MDR mediated by ABC transporters (Li et al., 2016; Ji et al., 2019) by lidocaine, indicating its ability to reverse the resistance of certain chemotherapeutics that are substrates of ABC transporters and warranting further research.

 Lidocaine Sensitizes Mitomycin C and Pirarubicin Without Showing Obvious Adverse Effects

Yang et al. evaluated the combination of lidocaine with other anticancer drugs, such as mitomycin C, pirarubicin, and Su Fu’ning lotion (an approved traditional Chinese medicine in China) on BIU-87 human bladder cancer cells and in a tumor-bearing mouse model. The results indicated lidocaine (1.25, 2.5, or 5 mg/mL, or 5.3, 10.6 or 21.3 μM) was a chemosensitizer as it enhanced the cytotoxicities of all three anticancer drugs, among which, the combination of lidocaine with mitomycin C was the most potent. In the in vivo test, this optimized combination exhibited lower body-weight loss and higher survival rates in vivo via intravesical administration compared to mitomycin C alone without showing any evidence of toxicity, suggesting a safe and promising therapy for the treatment of bladder cancer and warranting further research for the exact mechanisms (Yang X. et al., 2018).

 Lidocaine Sensitizes Hyperthermia Therapy via Regulating Cell Cycle and Heat Shock Proteins

Lidocaine was found to regulate the induction of heat shock proteins (HSPs) (Senisterra and Lepock, 2000), which could be applied in hyperthermia therapy. Raff et al. showed that in an in vitro study, lidocaine, at different concentrations (ranged from 0–0.3%), when combined with hyperthermia, exhibited selectivity to skin cancer cell lines and mucosal cancer cell line, such as human melanoma cells A375, murine basal cell carcinoma ASZ, and human cervical cancer cell line HeLa, over normal human keratinocytes (KertR) cells and human foreskin fibroblasts (HFF1). The combination treatment, 42°C of hyperthermia combined with 0.1–0.2% lidocaine, significantly inhibited the proliferation of cancer cell lines via cell arrest induction in S-phase, indicating the combination to be a promising regimen for selective killing of skin cancer cells (Raff et al., 2019).

The research above suggested that lidocaine (ranged from 1–100 μM) could work as a chemosensitizer to enhance the sensitivity of cisplatin, 5-FU, and mitomycin C. Its full potential remains to be explored and warrants further preclinical/clinical trials of these combination.

 Lidocaine Suppresses Cancer Growth

Lidocaine not only works as a chemosensitizer; it may also exert inhibitory effects toward various cancer cells and in tumor xenograft models by single use at higher concentrations.

Lung Cancer

Lung cancer, categorized into two main subtypes, small-cell lung cancer (SCLC) and NSCLC, is the primary cause of cancer-related death worldwide (Caballero et al., 2018; Arenberg, 2019). Lidocaine has been found to kill lung cancer cells in vitro and in vivo.

Beck-Schimmer’s group confirmed that certain amide-type local anesthetics, including lidocaine, could inhibit cancer cells by suppressing tumor necrosis factor alpha (TNFα)-induced Src activation, a mechanism related to its anti-inflammatory effects (Piegeler et al., 2015). Further study showed that lidocaine (1 nM to 100 μM, at clinically relevant concentrations) remarkably suppressed the activation/phosphorylation of AKT, focal adhesion kinase (FAK), and caveolin-1 induced by TNFα in lung adenocarcinoma NCI-H838 cells. Matrix-metalloproteinase 9 (MMP-9) is an enzyme that catalyzes the degradation of the extracellular matrix and basal lamina to allow migrating cancer cells to escape the primary tumor site, or to locate to a new spot to form the satellite lesions (El-Badrawy et al., 2014; Lee et al., 2015), which is important to from new solid tumors. Lidocaine significantly suppressed the MMP-9 secretion as confirmed by the immunosorbent assay, and it completely inhibited the cancer cell invasion, indicating its potential in preventing cancer invasion and metastasis (Piegeler et al., 2015). Another local anesthetic ropivacaine exhibited similar efficacy but at lower concentrations compared to lidocaine as shown in this study (Piegeler et al., 2015), which necessitates a broad screening of these type anesthetics.

To reveal more details on the mechanisms of the anticancer effects of lidocaine in lung cancer, Zhang et al. checked the related proteins by real-time quantitative PCR (qPCR) and Western blot assay in the samples of lung cancer patients. They confirmed that Golgi phosphor protein 2 (GOLPH2), a Golgi phosphoprotein that had been described as a potential serum marker of hepatocellular carcinoma, prostate cancer, and renal cell cancer (Duan et al., 2018; Li H. et al., 2018), was overexpressed in the patients with higher grade malignancy. Lidocaine (0.5, 2, and 8 mM, which were determined by MTT and BrdU assays) was found to suppress the expression of GOLPH2 in NSCLC A549 cells, leading to cell cycle arrest at the G1 phase and cell proliferation inhibition (Zhang et al., 2017).

In addition, lidocaine showed activity in suppressing postoperative atrial fibrillation (POAF), which occurs frequently after lung cancer surgery (Akkus and Oner, 2019), indicating its broad potent applications in lung cancer treatment.

 Breast Cancer

Breast cancer is the main cause of cancer-related deaths among females, accounting for approximately 7% of female cancer deaths due to uncontrolled metastasis (Anders et al., 2009; Vogel et al., 2011). Lidocaine exhibited activities in suppressing breast cancer growth.

C-X-C motif chemokine ligand 12 (CXCL12), and its receptor CXCR4, are proteins that regulate physiological and pathological processes, such as embryogenesis, angiogenesis, and inflammation (Del et al., 2018; Peled et al., 2018). Both proteins were found to be overexpressed in breast cancer (Wu et al., 2015; Smolkova et al., 2016). D’Agostino et al. found that, lidocaine, at 10 and 100 μM, reduced the motility of human breast cancer MDA-MB-231 cells as measured by the scratch wound assay and chemotaxis experiments. Further study indicated that the effects were mediated by the suppression of CXCL12/CXCR4 signaling, leading to the down-regulation of calcium (Ca2+) release and collapsed cytoskeleton remodeling, providing mechanistic insights of lidocaine in inhibiting cancer cell migration (D’Agostino et al., 2018).

Other mechanisms of metastasis inhibition induced by lidocaine in breast cancer cells might be attributed to its anti-inflammatory and anti-angiogenic effects according to a study in 4T1 breast cancer cell line in vitro and in vivo (Johnson et al., 2018). In this study, lidocaine (1.5 mg/kg, intravenous, followed by 25 min infusion at 2 mg/kg/h) showed no growth inhibition in tumor diameter, but it reduced the number of colony counts in lung and liver metastasis significantly via the inhibition of pro-inflammatory and angiogenic cytokine expression as tested in serum in animal models (Johnson et al., 2018). Similar results and mechanisms were also observed in Freeman et al.’s study (Freeman et al., 2019), indicating lidocaine’s role in suppressing metastasis of breast cancer via the suppression of pro-inflammation factors.

Given lidocaine’s effect in suppressing metastasis, its further application in various breast cancer cell lines, including normal breast epithelial cells MCF-10A, luminal breast cancer cell MCF-7, TNBC MDA-MB-231, and SKBr3 human epidermal growth factor receptor 2 (HER2) positive cells and in MDA-MB-231 cells xenograft model at clinically relevant concentrations were studied (Chamaraux-Tran et al., 2018). Lidocaine (0.1–10 mM determined by MTT assay) showed selectivity in suppressing the viability and migration of cancer cells over normal cells. Under clinically relevant dose for analgesia (100 mg/kg as adjusted according to the body surface area normalization method, injected intraperitoneally), lidocaine enhanced the survival rates in mice models of breast cancers (Chamaraux-Tran et al., 2018), warranting further preclinical/clinical studies.

Lirk et al. (2012) found that lidocaine (0.01, 0.1, and 1 mM) could demethylate DNA in both estrogen receptor (ER)-positive and -negative breast cancer cell lines (BT-20 and MCF-7 cells). This demethylation of DNA could finally lead to the inhibition of tumor growth and also provoke certain tumor suppressors, such as Ras association domain family 1 isoform A (RASSF1A), glutathione S-Transferase pi 1 (GSTP1), and myogenic differentiation 1 (MYOD1). Furthermore, the combination of lidocaine with another anticancer drug, 5-aza-2′-deoxycytidine, exerted synergistic demethylating effects (Lirk et al., 2014), suggesting that lidocaine regulates epigenetics—an underlying mechanism for its ability in suppressing tumor growth.

 Liver Cancer

Liver cancer, also known as hepatic cancer, is a type of cancer that starts in the liver. Liver cancer ranks as the sixth-most frequent cancer, and it’s one of the most rapidly progressing types of cancer. Lidocaine was also found to kill liver cancer cells.

Juri et al. examined and confirmed the inhibitory efficacies of lidocaine in the proliferation of human hepatocarcinoma HepG2 cells and normal liver fibroblasts LX2 cells. Their results showed that lidocaine (0.5–3 μM) could concentration-dependently suppress the cell viability of both cells, while it showed stronger inhibition to HepG2 cells, suggesting a selectivity profile. Mechanistic studies indicated that lidocaine down-regulated the expression of anti-apoptotic p53 in HepG2 cells, but not in LX2 cells (Jurj et al., 2017).

Another recent study conducted in vitro and in vivo by Xing et al. further confirmed lidocaine’s (0.1–10 mM) effects in inhibiting HepG2 cells growth (Xing et al., 2017) by inducing apoptosis through increasing the Bax/Bcl-2 ratio, an initial step in apoptosis activation (Adams et al., 2018), and activating caspase-3 via ERK1/2 and p38 pathways. Their mechanistic studies showed that lidocaine exerted its anticancer effects via cell cycle arrest at G0/G1 phase. More importantly, lidocaine not only reduced the tumor growth (30 mk/kg) through intraperitoneal injection, but also sensitized cisplatin in this animal study, indicating a combination therapy in treating hepatocellular carcinoma without exhibiting any obvious toxic effects (Xing et al., 2017).

Liu et al. (2018) evaluated the level of cytoplasmic polyadenylation element binding protein 3 (CPEB3) in liver cancer patients’ samples. They found that CPEB3 was down-regulated, leading to poor prognosis and high-grade malignancy (Liu et al., 2018). An in vitro study showed that lidocaine (0.1, 0.2, 0.5, 1, 2, 5, and 10 mM, as determined by cell counting kit-8 reagent) could up-regulate CPEB3 (at both mRNA and protein level), leading to the inhibition of proliferation and colony formation of HepG2 cells (Liu et al., 2018).

 Gastric Cancer

Gastric cancer ranks as the third leading reason for cancer-related deaths (Johnston and Beckman, 2019), with more than 1 million people newly diagnosed worldwide each year, causing a huge burden (Thrift and El-Serag, 2019). As one of the most-used local anesthetics in gastric cancer surgery, lidocaine also inhibits the proliferation of gastric cancer cells.

As shown in Sui’s study, lidocaine (1, 5, and 10 mM as determined by cell counting kit-8 reagent) suppressed the viability, migration, and invasion of gastric cancer MKN45 cells, meanwhile it induced more apoptosis. Further studies indicated that these effects were mediated, at least partially, by the up-regulation of miR-145, an important regulator of gastric cancer, which in turn inactivated the mitogen-activated protein kinase (MAPK)/ERK and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways. Transfection of miR-145 inhibitor showed contrary effects on the same cell line as compared to lidocaine, confirming a miR-145-mediated mechanism (Sui et al., 2019).

Another study conducted on human gastric cancer SGC7901 and BGC823 cells, lidocaine inhibited their proliferation, migration, and invasion and induced apoptosis in a concentration- (0.1–10 Mm, determined by MTT) and time- (0–72 h) dependent manner. Mechanistic studies showed that lidocaine increased the Bax/Bcl-2 ratio, increased the anti-apoptotic p-p38, and altered the MAPK expression, suggesting a mitochondria-mediated apoptosis pathway (Ye L. et al., 2019).

On gastric cancer cells AGS and HGC-27 cells, lidocaine (10 μM) suppressed the proliferation and migration, while it exerted no invasion inhibitory effects on both cancer cells. ERK1/2, key kinases playing pivotal roles in speeding the gastric cancer cells proliferation (Ahn et al., 2017), were down-regulated by lidocaine (Yang W. et al., 2018). Interestingly, another local anesthetic, ropivacaine was also found to possess similar efficacy as lidocaine as shown in this study (Yang W. et al., 2018).

Lidocaine not only worked in suppressing gastric cancer growth; it also exhibited potential in relieving persistent hiccups caused by gastric cancer (Kaneishi and Kawabata, 2013), suggesting its broad application in the treatment of gastric cancer and gastric cancer-related diseases/syndromes.

 Colorectal Cancer

Colorectal cancer, a type of cancer that develops in the colon or rectum, is more common in developed countries than in developing countries, possibly due to old age and different lifestyles, with more than 1 million new diagnosed cases worldwide each year as of recent (Siegel et al., 2017).

Qu et al. (2018) found that lidocaine (0.5, 1 mM, as determined by cell-counting kit-8 reagent) exhibited antiproliferative effects on colorectal cancer SW480 and HCT116 cells by inducing apoptosis via the suppression of epidermal growth factor receptor (EGFR) through upregulation of miR-520a-3p, whose target was EGFR. In addition, lidocaine (0.5 mM) could reverse miR-520a-3p reduction caused by miR-520a-3p inhibitor, confirming its mechanism involving with miR-520a-3p (Qu et al., 2018).

A recent study showed that lidocaine inhibited the growth of colon cancer cells lines HCT-116 (948.6 μM) and RKO (2,197 μM) cells via regulating the activation of apoptosis proteins, such as caspase-8, p53 protein, and survivin, as well as HSP-27 and HSP-60 (Tat et al., 2019).

Another study conducted in HT-29 and SW480 colon carcinoma cell lines, lidocaine (1 mM as determined by BrdU labeling solution) induced cell cycle arrest, but it showed no significant proliferation inhibition or apoptosis on both cell lines (Bundscherer et al., 2017).

 Melanoma

Melanoma is the most serious type of skin cancer and the leading cause of skin cancer related deaths, which can also be treated by certain concentrations of lidocaine.

Kang et al. (2016) found that lidocaine (2%), ropivacaine (0.75%), and their combination exhibited cytotoxic effects to melanoma cell lines A375 and Hs294T cells via the induction of apoptosis, and this effect was mediated through the activation of caspase-3 and caspase-8.

Another study conducted by Chen et al. showed that lidocaine (0.1, 3, and 5 mM, as determined by cell-counting kit-8 reagent) could kill A375 melanoma cells and suppress the colony formation in a concentration-dependent manner via cell cycle arrest at G1 phase (Chen et al., 2019). These effects were mediated by the down-regulation of Ki-67, a protein associated with cell proliferation and the cell division cycle (Robinson et al., 2018; Su and Chen, 2019), and down-regulation of phosphorylation of ERK. Importantly, lidocaine, via intravenous injections, significantly reduced the tumor volumes and weights in A375 cells xenograft mice model, indicating it a potential agent in combating melanoma (Chen et al., 2019).

Gao et al. examined the in vitro and in vivo effects of lidocaine on B16 melanoma cells. The results showed that lidocaine (50–200 μM, which were clinically relevant) inhibited cancer cells growth by inducing apoptosis. Mechanistic studies indicated that lidocaine cut the connections of matrigel and capillary formation, down-regulated vascular endothelial growth factor (VEGF)-activated VEGF receptor 2 (VEGFR2) phosphorylation, phospholipase Cγ (PLCγ)-protein kinase C (PKC)-MAPK, and FAK-paxillin in endothelial cells, leading to the inhibition of angiogenesis and cancer cells migration. Importantly, lidocaine (30 mg/kg), through intraperitoneal injection, significantly suppressed the angiogenesis and tumor growth in an animal model, suggesting its potential in treating melanoma by working as an angiogenesis inhibitor (Gao et al., 2019).

In addition, lidocaine (1.5 mg/kg) shortened the recovery of skin damage due to melanoma surgery, accelerated the wound healing, relieved the pain, and promoted the postoperative skin reconstruction (Xu et al., 2019), suggesting its potential in treating melanoma-related skin diseases.

 Glioma

Malignant glioma is a common brain cancer with limited therapy and terrible prognosis (Seliger and Hau, 2018). Lidocaine has been shown to kill glioma cells via the suppression of the transient receptor potential melastatin 7 (TRPM7), as shown in Leng et al.’s research (Leng et al., 2017). TRPM7, a subfamily of TRPM family proteins, regulates the entry of Ca2+ and Mg2+. It is a hallmark of many cancers, including head and neck cancer, ovarian cancer, prostate cancer, and pancreatic cancer, playing a key role in cell function and cell cycle (Zou et al., 2019). It is also a promising target in treating malignant glioma (Leng et al., 2015). Leng et al. (2017) found that lidocaine (1, 3 mM) inhibited 30–50% TRPM7 expression and suppressed the proliferation of rat C6 glioma cells and human A172 glioblastoma cells. Another study also showed that lidocaine (0–40 mM) might correlate with transient receptor potential cation channel subfamily V member 1 (TRPV1), leading to induction of apoptosis of U87-MG glioma cells via an increase of intracellular Ca2+ concentration and regulation of mitochondrial membrane potential (Lu et al., 2016).

A similar mechanism was also confirmed by Jiang et al., as they found that lidocaine (10 μM, 100 μM, and 1 mM) could regulate transient receptor potential cation channel subfamily V member 6 (TRPV6) in MDA-MB-231 cells, PC-3 prostatic cancer cells, and ES-2 ovarian cancer cells. Lidocaine, at lower-than-clinical concentrations, suppressed the invasion and migration of all three cancer cell lines. Lidocaine down-regulated the mRNA level and protein expression of TRPV6, leading to a reduction of Ca2+ influx (Jiang et al., 2016).

These studies suggested that lidocaine, as a voltage-gated Na(+) channel inhibitor, may exert its anticancer effects via regulating other cation channels.

 Tongue Cancer

Tongue cancer is a type of head and neck cancer that can be caused by smoking, drinking alcohol, and infection with the human papillomavirus (HPV) or Epstein-Barr virus (EBV) (Jiang et al., 2015).

In EGFR-overexpressing tongue cancer cell line, CAL27 cells, lidocaine suppressed the EGF-stimulated EGFR activity and inhibited the proliferation of CAL27 cells. This study suggested that by administering topically within the oral cavity, lidocaine cold suppress the proliferation of human tongue cancer cells (Sakaguchi et al., 2006). A recent study also confirmed the suppressing effects of lidocaine to the cell migration, growth, and survival of esophageal carcinoma at >100 μM, which was mediated by inhibiting mitochondrial respiration (Zhu et al., 2020).

 Discussion and Future Perspectives

The studies above indicate that lidocaine, besides its original anesthetic effect, could also act as an anticancer agent.

First, lidocaine could serve as a chemosensitizer, as it could markedly enhance the cytotoxicity of cisplatin in various cancer cells. Furthermore, lidocaine can sensitize 5-FU, cytomycin C, as well as the hyperthermia therapy, etc., to certain cancers in vitro and in vivo. Second, lidocaine had broad anticancer spectrum by single administration at various doses or concentrations, as it showed potential in suppressing lung cancer, breast cancer, gastric cancer, liver cancer, glioma, melanoma, and tongue cancer, etc., as summarized in Table 1 and Figure 2. The full potential of lidocaine in sensitizing other chemotherapeutics and combating cancer remains to be explored.

Summary of lidocaine in cancer treatment.

Category Applications Mechanisms/Targets References
Chemosensitizer Sensitizing cisplatin DNA demethylation PTEN/PI3K/AKT and PDCD4/JNK pathways Metastasis inhibition Li et al., 2014Yang Q. et al., 2019Freeman et al., 2018
Sensitizing 5-FU PI3K/AKT and Smad pathways ABC transporters regulation Wang et al., 2017Zhang et al., 2019
Sensitizing mitomycin C Sensitizing hyperthermia Unreported Cell cycle arrest and HSPs regulation Yang X. et al., 2018Raff et al., 2019
Anticancer agent Lung cancer MMP-9 or AKT/FAK pathways GOLPH2 Piegeler et al., 2015; Zhang et al., 2017
Breast cancer CXCL12/CXCR4 signaling Anti-inflammatory and anti-angiogenic effects Metastasis inhibition DNA demethylation D’Agostino et al., 2018Johnson et al., 2018Chamaraux-Tran et al., 2018Lirk et al., 2012
Liver cancer p53 inhibition Cell cycle arrest and apoptosis induction CPEB3 Jurj et al., 2017Xing et al., 2017Liu et al., 2018
Gastric cancer Up-regulation of miR-145 Mitochondria-mediated apoptosis pathway ERK1/2 Sui et al., 2019Ye L. et al., 2019Yang W. et al., 2018
Colorectal cancer miR-520a-3p Apoptosis induction Cell cycle arrest Qu et al., 2018Tat et al., 2019Bundscherer et al., 2017
Melanoma Apoptosis induction Ki-67 Anti-angiogenesis Kang et al., 2016Chen et al., 2019Gao et al., 2019
Glioma TRPM7 TRPV1 TRPV6 Leng et al., 2017Lu et al., 2016Jiang et al., 2016
Tongue cancer EGFR Mitochondrial respiration inhibition Sakaguchi et al., 2006Zhu et al., 2020

Overview of lidocaine in cancer treatment.

Currently, lidocaine is undergoing multiple clinical trials for the treatment of various cancer types and cancer-related symptoms, including an early phase I study for the prevention of recurrence of pancreatic cancer upon lidocaine (intravenous); a phase I for the prevention of recurrence of gastric carcinoma, colon cancer, rectal carcinoma, and liver cancer by injection of 0.5% lidocaine in normal saline to block peripheral nerve; and a phase III for better outcome of breast cancer via dermal infiltration of 2% lidocaine in incision site and regional breast and axillary areas (ClinicalTrials.gov Identifier: NCT04048278, NCT03134430, and NCT00938171). Some of these clinical trials are summarized in Table 2. Most of these clinical trials are in the early stages, the applications of lidocaine in cancer treatment are yet to be proved.

Several clinical trials using lidocaine in cancer treatmenta.

Phase/Year initiated Identification code Indications Status/Results
Early Phase I/2019 NCT04048278 Pancreatic cancer Recruiting/Not reported
Phase I/2017 NCT03134430 Cancer recurrence Active/Not reported
Phase III/2009 NCT00938171 Breast cancer Completed/Unrevealed
Phase II/2020 NCT04295330 Pain management in liver cancer Recruiting/Better efficacy and safety were observed
Phase I/2019 NCT04162535 Efficacy and prognosis of colorectal cancer Recruiting/Not reported
Phase II/2016 NCT02839668 Angiogenesis in breast cancer Completed/Unrevealed
Early Phase I/2016 NCT02786329 Chronic pain, cancer recurrences Recruiting/Not reported
Phase I/2018 NCT03530033 Muscle tumor in thyroid surgery Recruiting/Not reported
aDetails available at ClinicalTrials.gov.

In addition, as per the safety profile, lidocaine not only shows well-tolerant toxicity (Yang X. et al., 2018), selectivity in killing cancer cells over normal cells (Chamaraux-Tran et al., 2018), but also may alleviate cisplatin-induced body loss in the animal studies (Gao et al., 2018).

As reviewed in this paper, we noticed that the applied doses/concentrations of lidocaine varied when it came to different effects. For in vitro studies, lidocaine may work as chemosensitizer at relatively lower concentrations—for example, lower than 200 μM—while it requires a higher concentration to kill cancer cells, from 8 mM (Sun and Sun, 2019) up to 4 M (administered topically), which is unachievable in clinical practice, in killing tongue cancer cells (Sakaguchi et al., 2006). There is also research showing that under clinically relevant concentrations (0.1–200 μM), lidocaine exhibited anticancer efficacies. The plasma concentration of local anesthetics is at low μM, ranged from 2.5–10 μM, suggesting a suitable administrative method, such as local infiltration or administering topically, should be taken into account when used for killing cancer cells (Li R. et al., 2018; Zhu et al., 2020). More efforts, including the pharmacokinetics profile in vivo, are needed to verify its campatibal dose/concentration in certain treatments that are achievable in clinical practice.

Although the anticancer efficacies can be confirmed in various cancers, its exact mechanisms/targets remain unclear. As summarized in Table 1 and Figure 2, the reported targets/mechanisms include MMP-9 (Piegeler et al., 2015), ERK (Chen et al., 2019), TRPV6 (Jiang et al., 2016), and VEGF/VEGFR2 (Gao et al., 2019), as well as the regulation of epigenetics (Li et al., 2014), mi-RNA (Qu et al., 2018; Sui et al., 2019; Yang Q. et al., 2019), inhibition of metastasis (D’Agostino et al., 2018; Johnson et al., 2018; Sun and Sun, 2019), inhibition of inflammation (Freeman et al., 2019), impacting mitochondrial metabolism (Okamoto et al., 2017; Gong et al., 2018), the regulation of reactive oxygen species (ROS) (Okamoto et al., 2016), etc. Importantly, as an ion channel regulator, lidocaine may exert its anticancer effects via regulation of other channels or membrane potential, such as mitochondrial membrane potential (MMP), which may lead to the decrease of MMP, finally resulting in the mitochondria-related apoptosis (Li et al., 2014; Lu et al., 2016; Ye L. et al., 2019), providing valuable information for its targets identification. However, further studies are warranted to confirm its exact targets in different cancer types.

The information obtained about lidocaine could direct researchers to screen more local anesthetics for their cancer-inhibiting capabilities. Indeed, many local anesthetics have been confirmed to possess anticancer efficacies, such as morphine (Kim et al., 2016; Chen et al., 2017; Nishiwada et al., 2019), although it demonstrates contrasting results in cancer treatment (Harper et al., 2018; Tuerxun and Cui, 2019); procaine (Ma et al., 2016; Li C. et al., 2018; Li Y.C. et al., 2018); ropivacaine (Piegeler et al., 2015; Gong et al., 2018; Wang et al., 2019; Yang J. et al., 2019); bupivacaine (Xuan et al., 2016; Dan et al., 2018); and levobupivacaine (Jose et al., 2018; Li et al., 2019); as well as propofol (Xu et al., 2018; Kang et al., 2019; Zheng et al., 2019), etc.

As a chemosensitizer, certain combination strategies via different formulations can be designed and developed. Certain formulations composed of lidocaine with various anticancer drugs have been developed and they exhibit positive results in cancer treatment (Tabrizi and Chiniforoshan, 2016, 2017).

Furthermore, these studies also provide several leading scaffolds, namely, lidocaine, ropivacaine, and propofol, that may undergo structural modification to improve their activities and to avoid off-target effects. Examples include the palladium(II) complexes coordinated with lidocaine and phenylcyanamide derivatives as ligands (Tabrizi and Chiniforoshan, 2016, 2017), which have shown better antiproliferative effects than cisplatin. Series of propofol-derived analogs or derivatives have been synthesized and tested in various cancer cells and some of them exhibited favorable anticancer potency (Khan et al., 2011, 2012, 2013). These studies further strengthen the possibilities and potentials of using local anesthesia as anticancer agents; however, the outcomes can’t be overestimated until the structure–anticancer activity relationships are deciphered. Given that propofol, lidocaine, and ropivacaine possess different structures and pharmacophores, they may also exert their anticancer effects via different mechanisms. Further applications of these anesthesia in clinic will sure benefit from further studies of the exact action modes.

 Conclusion

Lidocaine, via various mechanisms, could suppress cancer growth in vitro and in vivo, providing valuable information for its further application in cancer treatment and for new drug discovery.

 Author Contributions

YX, PX, and QC conceived the idea. DZ, QC, and RI wrote the manuscript. LW, YX, and PX revised the manuscript. All authors contributed to the article and approved the submitted version.

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding. We thank the support of the Zhejiang Provincial Natural Science Foundation of China (Grant No. LY15H150005).

 References Adams C. M. Clark-Garvey S. Porcu P. Eischen C. M. (2018). Targeting the Bcl-2 family in B cell lymphoma. Front. Oncol. 8:636. 10.3389/fonc.2018.00636 Ahn S. Brant R. Sharpe A. Dry J. R. Hodgson D. R. Kilgour E. (2017). Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. Oncotarget 8 107492–107499. 10.18632/oncotarget.18182 Akkus M. Oner E. (2019). Can local infiltration of lidocaine reduce the postoperative atrial fibrillation rate in patients undergoing lobectomy for lung cancer?. Acta Chir. Belg. 23 1–6. 10.1080/00015458.2019.1610259 Anders C. K. Johnson R. Litton J. Phillips M. Bleyer A. (2009). Breast cancer before age 40 years. Semin. Oncol. 36 237–249. 10.1053/j.seminoncol.2009.03.001 Arenberg D. (2019). Update on screening for lung cancer. Transl. Lung. Cancer Res. 8 S77–S87. 10.21037/tlcr.2019.03.01 Begec Z. Gulhas N. Toprak H. I. Yetkin G. Kuzucu C. Ersoy M. O. (2007). Comparison of the antibacterial activity of lidocaine 1% versus alkalinized lidocaine in vitro. Curr. Ther. Res. Clin. Exp. 68 242–248. 10.1016/j.curtheres.2007.08.007 Bode A. M. Dong Z. (2018). Recent advances in precision oncology research. NPJ Precis. Oncol. 2:11. 10.1038/s41698-018-0055-0 Bundscherer A. C. Malsy M. Bitzinger D. I. Wiese C. H. Gruber M. A. Graf B. M. (2017). Effects of Lidocaine on HT-29 and SW480 colon cancer cells in vitro. Anticancer Res. 37 1941–1945. 10.21873/anticanres.11534 Caballero V. A. Garcia F. P. Romero O. A. Del M. R. Alcazar-Navarrete B. (2018). Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011-2016. J. Thorac. Dis. 10 5468–5475. 10.21037/jtd.2018.08.49 Caracas H. C. Maciel J. V. Martins P. M. de Souza M. M. Maia L. C. (2009). The use of lidocaine as an anti-inflammatory substance: a systematic review. J. Dent. 37 93–97. 10.1016/j.jdent.2008.10.005 Chamaraux-Tran T. N. Mathelin C. Aprahamian M. Joshi G. P. Tomasetto C. Diemunsch P. (2018). Antitumor effects of lidocaine on human breast cancer cells: an in vitro and in vivo experimental trial. Anticancer Res. 38 95–105. 10.21873/anticanres.12196 Chen J. Jiao Z. Wang A. Zhong W. (2019). Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation. J. Cell. Biochem. 120 6402–6408. 10.1002/jcb.27927 Chen Y. Qin Y. Li L. Chen J. Zhang X. Xie Y. (2017). Morphine can inhibit the growth of breast cancer MCF-7 cells by arresting the cell cycle and inducing apoptosis. Biol. Pharm. Bull. 40 1686–1692. 10.1248/bpb.b17-00215 Cruz F. F. Rocco P. R. Pelosi P. (2017). Anti-inflammatory properties of anesthetic agents. Crit. Care 21:67. 10.1186/s13054-017-1645-x Cui Q. Cai C. Y. Gao H. L. Ren L. Ji N. Gupta P. (2019a). Glesatinib, a c-MET/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells. Front. Oncol. 9:313. 10.3389/fonc.2019.00313 Cui Q. Wang J. Q. Assaraf Y. G. Ren L. Gupta P. Wei L. (2018a). Modulating ROS to overcome multidrug resistance in cancer. Drug. Resist. Updat. 41 1–25. 10.1016/j.drup.2018.11.001 Cui Q. Yang D. H. Chen Z. S. (2018b). Special issue: natural products: anticancer and beyond. Molecules 23 1246–1249. 10.3390/molecules23061246 Cui Q. Yang Y. Ji N. Wang J. Q. Ren L. Yang D. H. (2019b). Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. Future Med. Chem. 11 323–336. 10.4155/fmc-2018-0403 D’Agostino G. Saporito A. Cecchinato V. Silvestri Y. Borgeat A. Anselmi L. (2018). Lidocaine inhibits cytoskeletal remodelling and human breast cancer cell migration. Br. J. Anaesth. 121 962–968. 10.1016/j.bja.2018.07.015 Dan J. Gong X. Li D. Zhu G. Wang L. Li F. (2018). Inhibition of gastric cancer by local anesthetic Bupivacaine through multiple mechanisms independent of sodium channel blockade. Biomed. Pharmacother. 103 823–828. 10.1016/j.biopha.2018.04.106 Del M. D. B. I. Wilkins G. C. Meeson A. Ali S. Kirby J. A. (2018). Breast Cancer: an examination of the potential of ACKR3 to modify the response of CXCR4 to CXCL12. Int. J. Mol. Sci. 19:3592. 10.3390/ijms19113592 DeVita V. J. Chu E. (2008). A history of cancer chemotherapy. Cancer Res. 68 8643–8653. 10.1158/0008-5472.CAN-07-6611 Duan J. Li X. Huang S. Zeng Y. He Y. Liu H. (2018). GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma. Mol. Med. Rep. 17 4187–4194. 10.3892/mmr.2018.8430 El-Badrawy M. K. Yousef A. M. Shaalan D. Elsamanoudy A. Z. (2014). Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity, pathologic type, and prognosis. J. Bronchol. Interv. Pulmonol. 21 327–334. 10.1097/LBR.0000000000000094 Eroglu A. Ersoz C. Karasoy D. Sak S. (2017). Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: association with lymph node metastasis. Adv. Clin. Exp. Med. 26 245–249. 10.17219/acem/58784 Fan Y. F. Zhang W. Zeng L. Lei Z. N. Cai C. Y. Gupta P. (2018). Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett. 421 186–198. 10.1016/j.canlet.2018.01.021 Freeman J. Crowley P. D. Foley A. G. Gallagher H. C. Iwasaki M. Ma D. (2018). Effect of perioperative lidocaine and cisplatin on metastasis in a murine model of breast cancer surgery. Anticancer Res. 38 5599–5606. 10.21873/anticanres.12894 Freeman J. Crowley P. D. Foley A. G. Gallagher H. C. Iwasaki M. Ma D. (2019). Effect of perioperative lidocaine, propofol and steroids on pulmonary metastasis in a murine model of breast cancer surgery. Cancers 11:613. 10.3390/cancers11050613 Gao J. Hu H. Wang X. (2019). Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling. Cancer Chemother. Pharmacol. 83 1007–1015. 10.1007/s00280-019-03815-4 Gao X. Yang H. Wu M. Shi K. Zhou C. Peng J. (2018). Targeting delivery of lidocaine and cisplatin by nanogel enhances chemotherapy and alleviates metastasis. ACS Appl. Mater. Interfaces 10 25228–25240. 10.1021/acsami.8b09376 Gong X. Dan J. Li F. Wang L. (2018). Suppression of mitochondrial respiration with local anesthetic ropivacaine targets breast cancer cells. J. Thorac. Dis. 10 2804–2812. 10.21037/jtd.2018.05.21 Grandhi R. K. Perona B. (2019). Mechanisms of action by which local anesthetics reduce cancer recurrence: a systematic review. Pain Med. 21 401–414. 10.1093/pm/pnz139 Harjes U. (2018). Immunotherapy: tear down this wall. Nat. Rev. Immunol. 18:205. 10.1038/nri.2018.20 Harper P. Hald O. Lwaleed B. A. Kyyaly A. Johnston D. Cooper A. J. (2018). The impact of morphine treatment on bladder cancer cell proliferation and apoptosis: in vitro studies. Exp. Oncol. 40 190–193. 10.31768/2312-8852.2018.40(3):190-193 Harrison D. C. Collinsworth K. A. (1974). Antiarrhythmic actions of lidocaine. Annu. Rev. Med. 25 143–148. 10.1146/annurev.me.25.020174.001043 He J. Y. Wei X. H. Li S. J. Liu Y. Hu H. L. Li Z. Z. (2018). Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression. Cell Commun. Signal. 16:100. 10.1186/s12964-018-0309-z Ji N. Yang Y. Cai C. Y. Wang J. Q. Lei Z. N. Wu Z. X. (2019). Midostaurin reverses ABCB1-mediated multidrug resistance, an in vitro study. Front. Oncol. 9:514. 10.3389/fonc.2019.00514 Jiang R. Ekshyyan O. Moore-Medlin T. Rong X. Nathan S. Gu X. (2015). Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J. Oral. Pathol. Med. 44 28–36. 10.1111/jop.12221 Jiang Y. Gou H. Zhu J. Tian S. Yu L. (2016). Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation. Oncol. Lett. 12 1164–1170. 10.3892/ol.2016.4709 Johnson M. Z. Crowley P. D. Foley A. G. Xue C. Connolly C. Gallagher H. C. (2018). Effect of perioperative lidocaine on metastasis after sevoflurane or ketamine-xylazine anaesthesia for breast tumour resection in a murine model. Br. J. Anaesth. 121 76–85. 10.1016/j.bja.2017.12.043 Johnston F. M. Beckman M. (2019). Updates on management of gastric cancer. Curr. Oncol. Rep. 21:67. 10.1007/s11912-019-0820-4 Jose C. Hebert-Chatelain E. Dias A. N. Roche E. Obre E. Lacombe D. (2018). Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells. Redox Biol. 18 33–42. 10.1016/j.redox.2018.05.014 Jurj A. Tomuleasa C. Tat T. T. Berindan-Neagoe I. Vesa S. V. Ionescu D. C. (2017). Antiproliferative and apoptotic effects of lidocaine on human hepatocarcinoma cells. a preliminary study. J. Gastrointestin. Liver Dis. 26 45–50. 10.15403/jgld.2014.1121.261.juj Kaneishi K. Kawabata M. (2013). Continuous subcutaneous infusion of lidocaine for persistent hiccup in advanced cancer. Palliat. Med. 27 284–285. 10.1177/0269216312448508 Kang D. K. Zhao L. Y. Wang H. L. (2016). Cytotoxic effects of local anesthesia through lidocaine/ropivacaine on human melanoma cell lines. Braz. J. Anesthesiol. 66 594–602. 10.1016/j.bjane.2015.04.002 Kang F. C. Wang S. C. So E. C. Chang M. M. Wong K. L. Cheng K. S. (2019). Propofol may increase caspase and MAPK pathways, and suppress the Akt pathway to induce apoptosis in MA10 mouse Leydig tumor cells. Oncol. Rep. 41 3565–3574. 10.3892/or.2019.7129 Karlovich C. A. Williams P. M. (2019). Clinical applications of next-generation sequencing in precision oncology. Cancer J. 25 264–271. 10.1097/PPO.0000000000000385 Khan A. A. Alam M. Tufail S. Mustafa J. Owais M. (2011). Synthesis and characterization of novel PUFA esters exhibiting potential anticancer activities: an in vitro study. Eur. J. Med. Chem. 46 4878–4886. 10.1016/j.ejmech.2011.07.044 Khan A. A. Alanazi A. M. Jabeen M. Chauhan A. Abdelhameed A. S. (2013). Design, synthesis and in vitro anticancer evaluation of a stearic acid-based ester conjugate. Anticancer Res. 33 2517–2524. Khan A. A. Husain A. Jabeen M. Mustafa J. Owais M. (2012). Synthesis and characterization of novel n-9 fatty acid conjugates possessing antineoplastic properties. Lipids 47 973–986. 10.1007/s11745-012-3707-9 Kim J. Y. Ahn H. J. Kim J. K. Kim J. Lee S. H. Chae H. B. (2016). Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: an in vitro and human lung tissue study. Anesth. Analg. 123 1429–1436. 10.1213/ANE.0000000000001293 Kim R. Kawai A. Wakisaka M. Funaoka Y. Ohtani S. Ito M. (2017). Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. Clin. Transl. Med. 6:34. 10.1186/s40169-017-0163-4 Koh S. Y. Moon J. Y. Unno T. Cho S. K. (2019). Baicalein suppresses stem cell-like characteristics in radio- and chemoresistant MDA-MB-231 human breast cancer cells through up-regulation of IFIT2. Nutrients 11:624. 10.3390/nu11030624 Lee C. Y. Shim H. S. Lee S. Lee J. G. Kim D. J. Chung K. Y. (2015). Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer. J. Cardiothorac. Surg. 10:44. 10.1186/s13019-015-0248-3 Lee Y. T. Tan Y. J. Oon C. E. (2018). Molecular targeted therapy: treating cancer with specificity. Eur. J. Pharmacol. 834 188–196. 10.1016/j.ejphar.2018.07.034 Leng T. Lin S. Xiong Z. Lin J. (2017). Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels. Int. J. Physiol. Pathophysiol. Pharmacol. 9 8–15. Leng T. D. Li M. H. Shen J. F. Liu M. L. Li X. B. Sun H. W. (2015). Suppression of TRPM7 inhibits proliferation, migration, and invasion of malignant human glioma cells. CNS Neurosci. Ther. 21 252–261. 10.1111/cns.12354 Li C. Gao S. Li X. Li C. Ma L. (2018). Procaine inhibits the proliferation and migration of colon cancer cells through inactivation of the ERK/MAPK/FAK pathways by regulation of RhoA. Oncol. Res. 26 209–217. 10.3727/096504017X14944585873622 Li H. Yang L. L. Xiao Y. Deng W. W. Chen L. Wu L. (2018). Overexpression of Golgi phosphoprotein 2 is associated with poor prognosis in oral squamous cell carcinoma. Am. J. Clin. Pathol. 150 74–83. 10.1093/ajcp/aqy029 Li K. Yang J. Han X. (2014). Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARbeta2 and RASSF1A demethylation. Int. J. Mol. Sci. 15 23519–23536. 10.3390/ijms151223519 Li R. Xiao C. Liu H. Huang Y. Dilger J. P. Lin J. (2018). Effects of local anesthetics on breast cancer cell viability and migration. BMC Cancer 18:666. 10.1186/s12885-018-4576-2 Li T. Chen L. Zhao H. Wu L. Masters J. Han C. (2019). Both Bupivacaine and Levobupivacaine inhibit colon cancer cell growth but not melanoma cells in vitro. J. Anesth. 33 17–25. 10.1007/s00540-018-2577-6 Li W. Zhang H. Assaraf Y. G. Zhao K. Xu X. Xie J. (2016). Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug. Resist. Updat. 27 14–29. 10.1016/j.drup.2016.05.001 Li Y. C. Wang Y. Li D. D. Zhang Y. Zhao T. C. Li C. F. (2018). Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer. J. Cell. Biochem. 119 2440–2449. 10.1002/jcb.26407 Lirk P. Berger R. Hollmann M. W. Fiegl H. (2012). Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro. Br. J. Anaesth. 109 200–207. 10.1093/bja/aes128 Lirk P. Hollmann M. W. Fleischer M. Weber N. C. Fiegl H. (2014). Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro. Br. J. Anaesth. 113 (Suppl. 1), i32–i38. 10.1093/bja/aeu201 Liu H. Wang Y. Chen B. Shen X. Li W. (2018). Effects of Lidocaine-mediated CPEB3 upregulation in human hepatocellular carcinoma cell proliferation in vitro. Biomed. Res. Int. 2018:8403157. 10.1155/2018/8403157 Lu J. Ju Y. T. Li C. Hua F. Z. Xu G. H. Hu Y. H. (2016). Effect of TRPV1 combined with lidocaine on cell state and apoptosis of U87-MG glioma cell lines. Asian Pac. J. Trop. Med. 9 288–292. 10.1016/j.apjtm.2016.01.030 Ma X. W. Li Y. Han X. C. Xin Q. Z. (2016). The effect of low dosage of procaine on lung cancer cell proliferation. Eur. Rev. Med. Pharmacol. Sci. 20 4791–4795. Macchiarulo A. (2017). Immunotherapy. a pursuit race to tomorrow’s medicines. Future Med. Chem. 9 1297–1299. 10.4155/fmc-2017-0129 Medeiros B. Allan A. L. (2019). Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int. J. Mol. Sci. 20:2272. 10.3390/ijms20092272 Mittra A. Moscow J. A. (2019). Future approaches to precision oncology-based clinical trials. Cancer J. 25 300–304. 10.1097/PPO.0000000000000383 Mottino A. (2019). ABC transporters: from basic knowledge to potential clinical application. Curr. Med. Chem. 26 1060–1061. 10.2174/092986732607190514073051 Nikitaki Z. Michalopoulos I. Georgakilas A. G. (2015). Molecular inhibitors of DNA repair: searching for the ultimate tumor killing weapon. Future Med. Chem. 7 1543–1558. 10.4155/fmc.15.95 Nishiwada T. Kawaraguchi Y. Uemura K. Kawaguchi M. (2019). Morphine inhibits cell viability and growth via suppression of vascular endothelial growth factor in human oral cancer HSC-3 cells. J. Anesth. 33 408–415. 10.1007/s00540-019-02645-1 Nowacka A. Borczyk M. (2019). Ketamine applications beyond anesthesia - a literature review. Eur. J. Pharmacol. 860:172547. 10.1016/j.ejphar.2019.172547 Okamoto A. Sumi C. Tanaka H. Kusunoki M. Iwai T. Nishi K. (2017). HIF-1-mediated suppression of mitochondria electron transport chain function confers resistance to lidocaine-induced cell death. Sci. Rep. 7:3816. 10.1038/s41598-017-03980-7 Okamoto A. Tanaka M. Sumi C. Oku K. Kusunoki M. Nishi K. (2016). The antioxidant N-acetyl cysteine suppresses lidocaine-induced intracellular reactive oxygen species production and cell death in neuronal SH-SY5Y cells. BMC Anesthesiol. 16:104. 10.1186/s12871-016-0273-3 Palazzo A. Iacovelli R. Cortesi E. (2010). Past, present and future of targeted therapy in solid tumors. Curr. Cancer Drug. Targets 10 433–461. 10.2174/156800910791517145 Pavan B. Paganetto G. Rossi D. Dalpiaz A. (2014). Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug. Discov. Today 19 1563–1571. 10.1016/j.drudis.2014.06.004 Peled A. Klein S. Beider K. Burger J. A. Abraham M. (2018). Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine 109 11–16. 10.1016/j.cyto.2018.02.020 Piegeler T. Schlapfer M. Dull R. O. Schwartz D. E. Borgeat A. Minshall R. D. (2015). Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNFalpha-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase. Br. J. Anaesth. 115 784–791. 10.1093/bja/aev341 Prasad V. Fojo T. Brada M. (2016). Precision oncology: origins, optimism, and potential. Lancet Oncol. 17 e81–e86. 10.1016/S1470-2045(15)00620-8 Pushpakom S. Iorio F. Eyers P. A. Escott K. J. Hopper S. Wells A. (2018). Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18 41–58. 10.1038/nrd.2018.168 Qu X. Yang L. Shi Q. Wang X. Wang D. Wu G. (2018). Lidocaine inhibits proliferation and induces apoptosis in colorectal cancer cells by upregulating mir-520a-3p and targeting EGFR. Pathol. Res. Pract. 214 1974–1979. 10.1016/j.prp.2018.09.012 Raff A. B. Thomas C. N. Chuang G. S. Avram M. M. Le M. H. Anderson R. R. (2019). Lidocaine-induced potentiation of thermal damage in skin and carcinoma cells. Lasers Surg. Med. 51 88–94. 10.1002/lsm.23027 Re A. Nardella C. Quattrone A. Lunardi A. (2018). Editorial: precision medicine in oncology. Front. Oncol. 8:479. 10.3389/fonc.2018.00479 Ren L. Huang C. Liu Y. H. Yu Y. Lin L. Wen L. J. (2016). The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain. Zhonghua Yi Xue Za Zhi 96 1454–1458. 10.3760/cma.j.issn.0376-2491.2016.18.014 Riganti C. Mini E. Nobili S. (2015). Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. Front. Oncol. 5:105. 10.3389/fonc.2015.00105 Robinson E. M. Rosenbaum B. E. Zhang Y. Rogers R. Tchack J. Berman R. S. (2018). Association between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging. J. Surg. Oncol. 118 150–156. 10.1002/jso.25111 Sakaguchi M. Kuroda Y. Hirose M. (2006). The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth. Analg. 102 1103–1107. 10.1213/01.ane.0000198330.84341.35 Salgado R. Moore H. Martens J. Lively T. Malik S. McDermott U. (2018). Steps forward for cancer precision medicine. Nat. Rev. Drug Discov. 17 1–2. 10.1038/nrd.2017.218 Sambi M. Bagheri L. Szewczuk M. R. (2019). Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J. Oncol. 2019:4508794. 10.1155/2019/4508794 Seliger C. Hau P. (2018). Drug repurposing of metabolic agents in malignant glioma. Int. J. Mol. Sci. 19:2768. 10.3390/ijms19092768 Senisterra G. A. Lepock J. R. (2000). Thermal destabilization of transmembrane proteins by local anaesthetics. Int. J. Hyperthermia 16 1–17. 10.1080/026567300285385 Serafin M. B. Bottega A. Da R. T. Machado C. S. Foletto V. S. Coelho S. S. (2019). Drug repositioning in oncology. Am. J. Ther. Online ahead of print. 10.1097/MJT.0000000000000906 Siegel R. L. Miller K. D. Fedewa S. A. Ahnen D. J. Meester R. Barzi A. (2017). Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67 177–193. 10.3322/caac.21395 Smolkova B. Mego M. Horvathova K. V. Cierna Z. Danihel L. Sedlackova T. (2016). Expression of SOCS1 and CXCL12 proteins in primary breast cancer are associated with presence of circulating tumor cells in peripheral blood. Transl. Oncol. 9 184–190. 10.1016/j.tranon.2016.03.004 Su F. F. Chen J. L. (2019). Expression and clinical significance of p16 and Ki-67 in malignant melanoma of the conjunctiva. J. Biol. Regul. Homeost. Agents 33 821–825. Sui H. Lou A. Li Z. Yang J. (2019). Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer 19:233. 10.1186/s12885-019-5431-9 Sun G. Zhao L. Zhong R. Peng Y. (2018). The specific role of O(6)-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy. Future Med. Chem. 10 1971–1996. 10.4155/fmc-2018-0069 Sun H. Sun Y. (2019). Lidocaine inhibits proliferation and metastasis of lung cancer cell via regulation of miR-539/EGFR axis. Artif. Cells Nanomed. Biotechnol. 47 2866–2874. 10.1080/21691401.2019.1636807 Swain S. Sahu P. K. Beg S. Babu S. M. (2016). Nanoparticles for cancer targeting: current and future directions. Curr. Drug Deliv. 13 1290–1302. 10.2174/1567201813666160713121122 Tabrizi L. Chiniforoshan H. (2016). New water-soluble palladium(II) complexes of lidocaine and phenylcyanamide derivative ligands: cytotoxicity and cellular response mechanisms. Invest. New Drugs 34 723–732. 10.1007/s10637-016-0393-0 Tabrizi L. Chiniforoshan H. (2017). Cytotoxicity and cellular response mechanisms of water-soluble platinum(II) complexes of lidocaine and phenylcyanamide derivatives. Biometals 30 59–70. 10.1007/s10534-016-9986-5 Tang H. Zeng L. Wang J. Zhang X. Ruan Q. Wang J. (2017). Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer. Oncotarget 8 82842–82853. 10.18632/oncotarget.20666 Tat T. Jurj A. Selicean C. Pasca S. Ionescu D. (2019). Antiproliferative effects of propofol and lidocaine on the colon adenocarcinoma microenvironment. J. Buon. 24 106–115. Thi-Kim N. Y. Moon J. Y. Ryu J. Y. Eum S. Bach T. T. Cho S. K. (2019). Methanol extract of aerial parts of pavetta indica l. enhances the cytotoxic effect of doxorubicin and induces radiation sensitization in MDA-MB-231 triple-negative breast cancer cells. Molecules 24:2273. 10.3390/molecules24122273 Thrift A. P. El-Serag H. B. (2019). Burden of gastric cancer. Clin. Gastroenterol. Hepatol. 18 534–542. 10.1016/j.cgh.2019.07.045 Tian J. Gu Y. Su D. Wu Y. Wang X. (2009). Effects of intrathecal lidocaine on hyperalgesia and allodynia following chronic constriction injury in rats. Eur. J. Pain 13 130–137. 10.1016/j.ejpain.2008.03.013 Tiwari A. K. Chen Z. S. (2013). Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. Front. Pharmacol. 4:82. 10.3389/fphar.2013.00082 Tuerxun H. Cui J. (2019). The dual effect of morphine on tumor development. Clin. Transl. Oncol. 21 695–701. 10.1007/s12094-018-1974-5 Vogel J. E. Chu C. McCullough M. Anderson E. Losken A. Carlson G. W. (2011). Breast cancer in women under age 40 years: treatment by total mastectomy and reconstruction. Ann. Plast. Surg. 66 557–560. 10.1097/SAP.0b013e318216b648 Wang J. Q. Li J. Y. Teng Q. X. Lei Z. N. Ji N. Cui Q. (2020). Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated mdr cancer cells. Cancers 12:466. 10.3390/cancers12020466 Wang W. Zhu M. Xu Z. Li W. Dong X. Chen Y. (2019). Ropivacaine promotes apoptosis of hepatocellular carcinoma cells through damaging mitochondria and activating caspase-3 activity. Biol. Res. 52:36. 10.1186/s40659-019-0242-7 Wang Y. Xie J. Liu W. Zhang R. Huang S. Xing Y. (2017). Lidocaine sensitizes the cytotoxicity of 5-fluorouacil in melanoma cells via upregulation of microRNA-493. Pharmazie 72 663–669. 10.1691/ph.2017.7616 Wen Y. H. Lee T. Y. Fu P. C. Lo C. L. Chiang Y. T. (2017). Multifunctional polymer nanoparticles for dual drug release and cancer cell targeting. Polymers 9:213. 10.3390/polym9060213 Wise H. C. Solit D. B. (2019). Precision oncology: three small steps forward. Cancer Cell 35 825–826. 10.1016/j.ccell.2019.05.009 Wu W. Qian L. Chen X. Ding B. (2015). Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. Int. J. Clin. Exp. Pathol. 8 13217–13224. Xing W. Chen D. T. Pan J. H. Chen Y. H. Yan Y. Li Q. (2017). Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology 126 868–881. 10.1097/ALN.0000000000001528 Xu K. Wang J. Yang L. Wan L. Wang Y. (2019). Effect of lidocaine on the safety of postoperative skin reconstruction after malignant melanoma resection. Exp. Ther. Med. 18 949–954. 10.3892/etm.2019.7519 Xu W. Zheng J. Bie S. Kang L. Mao Q. Liu W. (2018). Propofol inhibits Wnt signaling and exerts anticancer activity in glioma cells. Oncol. Lett. 16 402–408. 10.3892/ol.2018.8606 Xuan W. Zhao H. Hankin J. Chen L. Yao S. Ma D. (2016). Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro. Sci. Rep. 6:26277. 10.1038/srep26277 Yang J. Li G. Bao K. Liu W. Zhang Y. Ting W. (2019). Ropivacaine inhibits tumor angiogenesis via sodium-channel-independent mitochondrial dysfunction and oxidative stress. J. Bioenerg. Biomembr. 51 231–238. 10.1007/s10863-019-09793-9 Yang Q. Zhang Z. Xu H. Ma C. (2019). Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21. Mol. Cell. Biochem. 456 63–72. 10.1007/s11010-018-3490-x Yang W. Cai J. Zhang H. Wang G. Jiang W. (2018). Effects of lidocaine and ropivacaine on gastric cancer cells through down-regulation of ERK1/2 phosphorylation in vitro. Anticancer Res. 38 6729–6735. 10.21873/anticanres.13042 Yang X. Zhao L. Li M. Yan L. Zhang S. Mi Z. (2018). Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. Sci. Rep. 8:598. 10.1038/s41598-017-19026-x Yap A. Lopez-Olivo M. A. Dubowitz J. Hiller J. Riedel B. (2019). Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can. J. Anaesth. 66 546–561. 10.1007/s12630-019-01330-x Ye L. Zhang Y. Chen Y. J. Liu Q. (2019). Anti-tumor effects of lidocaine on human gastric cancer cells in vitro. Bratisl. Lek. Listy 120 212–217. 10.4149/BLL_2019_036 Ye Q. Liu K. Shen Q. Li Q. Hao J. Han F. (2019). Reversal of multidrug resistance in cancer by multi-functional flavonoids. Front. Oncol. 9:487. 10.3389/fonc.2019.00487 Zhang L. Hu R. Cheng Y. Wu X. Xi S. Sun Y. (2017). Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A. Cell Prolif. 50:e12364. 10.1111/cpr.12364 Zhang X. Pang W. Liu H. Wang J. (2019). Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression. J. Cell. Biochem. 120 16533–16542. 10.1002/jcb.28913 Zheng H. Fu Y. Yang T. (2019). Propofol inhibits proliferation, migration, and invasion of hepatocellular carcinoma cells by downregulating twist. J. Cell. Biochem. 120 12803–12809. 10.1002/jcb.28551 Zhu G. Zhang L. Dan J. Zhu Q. (2020). Differential effects and mechanisms of local anesthetics on esophageal carcinoma cell migration, growth, survival and chemosensitivity. BMC Anesthesiol. 20:126. 10.1186/s12871-020-01039-1 Zou Z. G. Rios F. J. Montezano A. C. Touyz R. M. (2019). TRPM7, magnesium, and signaling. Int. J. Mol. Sci. 20:1877. 10.3390/ijms20081877